Research Analysts Issue Forecasts for Merus Labs International Inc.’s Q1 2024 Earnings (TSE:MSL)

Merus Labs International Inc. (TSE:MSL) (NASDAQ:MSLI) – Analysts at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for shares of Merus Labs International in a research report issued to clients and investors on Monday, April 15th. HC Wainwright analyst A. He anticipates that the specialty pharmaceutical company will post earnings of ($0.05) per share for the quarter. HC Wainwright currently has a “Buy” rating on the stock. HC Wainwright also issued estimates for Merus Labs International’s Q2 2024 earnings at ($0.05) EPS, Q3 2024 earnings at ($0.05) EPS, Q4 2024 earnings at ($0.05) EPS, FY2024 earnings at ($0.19) EPS, Q1 2025 earnings at ($0.05) EPS, Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.20) EPS, FY2026 earnings at ($0.18) EPS, FY2027 earnings at ($0.23) EPS and FY2028 earnings at ($0.22) EPS.

Merus Labs International Stock Performance

The business’s fifty day simple moving average is C$1.65. Merus Labs International has a 12 month low of C$0.95 and a 12 month high of C$1.76.

Merus Labs International (TSE:MSL) (NASDAQ:MSLI) last announced its quarterly earnings data on Wednesday, March 27th. The specialty pharmaceutical company reported C($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of C($0.01) by C($0.05).

Merus Labs International Company Profile

Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.